You can buy or sell IONS and other stocks, options, ETFs, and crypto commission-free!
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. Read More The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
52 Week High
52 Week Low
Seeking AlphaMay 24
Ionis down 2% on FDA nod for Novartis gene therapy for SMA1
Ionis Pharmaceuticals (IONS -2.2% ) is under modest pressure on the heels of the FDA's OK of Novartis' gene therapy Zolgensma for spinal muscular atrophy Type 1 (SMA1). Ionis out-licensed nusinersen, branded as Spinraza, to Biogen. The FDA approved it in December 2016 for SMA....
Yahoo FinanceMay 14
Ionis Pharmaceuticals Is 40% of the Way There
Ionis Pharmaceuticals (NASDAQ: IONS) started the year off on a positive note, doubling revenue in the first quarter thanks to a large licensing payment from one of its partners.
Yahoo FinanceMay 9
Ionis Pharmaceuticals, Inc. Q1 2019 Earnings Call Transcript
Image source: The Motley Fool. Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) Q1 2019 Earnings Call , 11:30 a.m. ET Operator Good morning and welcome to the Ionis Pharmaceuticals Q1 2019 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke, Vice President, Investor Relations to lead off the call. Please begin. Wade Walke -- Vice President, Investor Relations Thank you, Gary. Before we begin, I encourage everyone to ...
Expected Aug 6, Pre-Market